Inhibrx Biosciences, Inc. has announced its financial results for the third quarter of 2026, revealing a net loss of $38.7 million. This update is significant as it reflects the company's ongoing challenges in the competitive biopharmaceutical landscape while continuing to advance its clinical programs. The results are particularly relevant for stakeholders interested in the performance and future prospects of the company.

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel biologic therapeutic candidates. The company operates under the Standard Industrial Classification (SIC) code 2836, which pertains to Biological Products (No Diagnostic Substances). Inhibrx is traded on the Nasdaq under the ticker symbol INBX. The company has been active in filing reports, including a recent 10-Q and S-3ASR, alongside this 8-K.

The recent filing details that on November 13, 2026, Inhibrx issued a press release outlining its financial results for the three and nine months ended September 30, 2026. The press release is included as Exhibit 99.1 in the filing. The company reported a significant net loss of $38.7 million during the third quarter, compared to a net loss of $35.3 million for the same period in 2025. This translates to a loss of $2.46 per share, basic and diluted.

Inhibrx's financial results also highlighted key components of its operations. The company recognized $2.0 million in revenue during the third quarter under a licensing agreement with Pfizer, marking a notable increase from no revenue in the same quarter of the previous year. The company had cash and cash equivalents of $199.5 million as of September 30, 2026, providing a buffer as it continues to invest in its clinical trials.

Additionally, the filing indicates that Inhibrx is actively advancing its clinical programs, particularly with its lead candidates, ozekibart (INBRX-109) and ordastobart (INBRX-106). The company plans to present updated results for ozekibart at the upcoming Connective Tissue Oncology Society meeting in Seoul, South Korea, scheduled for November 19-20, 2026. This presentation is expected to provide further insights into the drug's efficacy in treating Ewing sarcoma.

The ongoing development of ozekibart in chondrosarcoma and ordastobart in head and neck squamous cell carcinoma (HNSCC) demonstrates Inhibrx's commitment to addressing unmet medical needs. The company is currently enrolling patients in the Phase 2 portion of its HexAgon study for ordastobart, which is expected to yield initial results around mid-2027.

The financial landscape for Inhibrx and its competitors remains challenging, particularly as research and development expenses continue to rise. The company reported a decrease in research and development expenses to $26.0 million for the third quarter of 2026, down from $28.5 million in the same period last year. This decrease was attributed to the completion of enrollment in trials and reduced personnel-related expenses, offset by increased contract manufacturing costs.

General and administrative expenses also saw an increase, rising to $7.8 million compared to $5.3 million in the previous year. This increase is primarily linked to pre-commercialization activities as the company prepares for potential product launches.

In summary, Inhibrx's financial results for Q3 2026 reflect both the challenges and opportunities inherent in the biopharmaceutical industry. As the company continues to advance its clinical trials and manage its financial health, stakeholders will be closely monitoring its progress. The filing does not specify what actions the company may take next, but the upcoming clinical milestones and financial management strategies will be critical in shaping its future.